Quanterix Corporation reported fourth‑quarter 2025 results that surpassed revenue expectations but fell short on profitability. Total revenue rose to $43.9 million, a 25 % increase from the same period a year earlier, while the company posted a net loss of $23.1 million and earnings per share of $‑0.49, missing the consensus estimate of $‑0.27. The earnings miss was driven by higher integration and restructuring costs following the Akoya acquisition and a broader decline in organic revenue, which fell 22 % year‑over‑year.
The company’s GAAP gross margin contracted to 45.7 % in Q4 2025 from 63.0 % in Q4 2024, reflecting an 83 % year‑over‑year rise in cost of sales to $23.8 million. The margin compression underscores the impact of higher raw‑material and labor costs, as well as the one‑time expenses associated with the Akoya integration. Non‑GAAP gross margin remained more stable at 50 % versus 57.7 % in the prior year, indicating that the core operating model still retains some pricing power.
Management guidance for 2026 remains optimistic. The company forecasts full‑year revenue of $169 million to $174 million, a 22 % to 25 % increase from 2025, and projects a GAAP gross margin of 45 % to 49 %. Quanterix reiterated its target to achieve cash‑flow breakeven in the second half of 2026, citing progress in its Simoa ONE platform and the LucentAD Alzheimer’s blood test. The guidance signals confidence in the company’s strategic initiatives while acknowledging the need to manage integration costs.
"I am thrilled to be joining Quanterix at a time when the company is well‑positioned to deliver long‑term growth," said President & CEO Everett Cunningham. "During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer's Diagnostics business." He added, "My immediate focus is on spending time with the Quanterix team, customers, shareholders, and partners as I evaluate the Company’s strategy and future potential and ensure that we have the resources, support and capabilities to deliver on our operational priorities."
Chief Financial Officer Vandana Sriram noted, "Total revenue for the fourth quarter was $43.9 million, an increase of 25 % from the previous year, up 7 % sequentially." She added, "Organic revenue was a decline of 22 %. We have already implemented $74 million of our $85 million cost synergy target, and we’re on track to meet our target by the end of Q1." She also said, "We expect to report approximately $169 million to $174 million of revenue, which assumes no underlying improvement in the academic or pharmaceutical end markets."
Investors focused on the EPS miss and margin compression, which tempered enthusiasm for the revenue beat. The company’s ability to generate strong top‑line growth amid a challenging cost environment remains a key concern for analysts and shareholders alike.
The earnings report highlights a critical juncture for Quanterix: while revenue growth is largely driven by the Akoya acquisition, the company must navigate margin compression and a widening net loss to reach profitability. The guidance for 2026 reflects confidence in the company’s strategic initiatives, but the EPS miss and cost pressures underscore the need for disciplined execution as the firm moves toward cash‑flow breakeven.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.